Nanocolloidosomes with Selective Drug Release for Active Tumor-Targeted Imaging-Guided Photothermal/Chemo Combination Therapy

2017 ◽  
Vol 9 (48) ◽  
pp. 42225-42238 ◽  
Author(s):  
Hang Hu ◽  
Chen Xiao ◽  
Honglian Wu ◽  
Yihui Li ◽  
Qing Zhou ◽  
...  
Keyword(s):  
Drug Release ◽  
Combination Therapy ◽  
Targeted Imaging

scholarly journals Correction to Supramolecular Drug–Drug Complex Vesicles Enable Sequential Drug Release for Enhanced Combination Therapy

2020 ◽  
Vol 12 (39) ◽  
pp. 44382-44382
Author(s):  
Chengfei Liu ◽  
Chunpu Li ◽  
Cui Pang ◽  
Muqiong Li ◽  
Huixin Li ◽  
...  
Keyword(s):  
Drug Release ◽  
Combination Therapy ◽  
Sequential Drug Release ◽  
Drug Complex

scholarly journals Multifunctional Cargo-Free Nanomedicine for Cancer Therapy

2018 ◽  
Vol 19 (10) ◽  
pp. 2963 ◽  
Author(s):  
Ying Wang ◽  
Pengfei Yang ◽  
Xinrui Zhao ◽  
Di Gao ◽  
Na Sun ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Cancer Therapy ◽  
Drug Release ◽  
Combination Therapy ◽  
Cancer Treatment ◽  
Clinical Applications ◽  
Self Monitoring ◽  
Promising Strategy ◽  
Carrier Free ◽  
Future Challenges

Nanocarriers encapsulating multiple chemotherapeutics are a promising strategy to achieve combinational chemotherapy for cancer therapy; however, they generally use exotic new carriers without therapeutic effect, which usually suffer from carrier-related toxicity issues, as well as having to pass extensive clinical trials to be drug excipients before any clinical applications. Cargo-free nanomedicines, which are fabricated by drugs themselves without new excipients and possess nanoscale characteristics to realize favorable pharmacokinetics and intracellular delivery, have been rapidly developed and drawn much attention to cancer treatment. Herein, we discuss recent advances of cargo-free nanomedicines for cancer treatment. After a brief introduction to the major types of carrier-free nanomedicine, some representative applications of these cargo-free nanomedicines are discussed, including combination therapy, immunotherapy, as well as self-monitoring of drug release. More importantly, this review draws a brief conclusion and discusses the future challenges of cargo-free nanomedicines from our perspective.

An albumin-binding dimeric prodrug nanoparticle with long blood circulation and light-triggered drug release for chemo-photodynamic combination therapy against hypoxia-induced metastasis of lung cancer

2021 ◽  
Author(s):  
Renjie Luo ◽  
Zhongtao Zhang ◽  
Lingfei Han ◽  
Zhen Xue ◽  
Kexin Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Drug Release ◽  
Combination Therapy ◽  
Blood Circulation ◽  
Albumin Binding ◽  
Triggered Drug Release

An albumin-binding and light-triggered chemo-photodynamic therapeutic nanoplatform (Ce6&DHA-S-DHA@CMN NPs) was used for inhibiting hypoxia-induced metastasis of lung cancer.

Multifunctional theranostic nanosystems enabling photothermal-chemo combination therapy of triple-stimuli-responsive drug release with magnetic resonance imaging

2020 ◽  
Vol 8 (7) ◽  
pp. 1875-1884 ◽  
Author(s):  
Xiao Lin ◽  
Xiaofang Song ◽  
Yiwei Zhang ◽  
Yanbing Cao ◽  
Yanan Xue ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Drug Release ◽  
Combination Therapy ◽  
Thermal Imaging ◽  
Stimuli Responsive ◽  
Resonance Imaging

As a multifunctional theranostic nanoplatform, FPCH-DOX NPs enable triple-stimuli responsive drug release for MR/thermal imaging-guided photothermal-chemo combination therapy.

scholarly journals ROS-responsive liposomes with NIR light-triggered doxorubicin release for combinatorial therapy of breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Hanxi Yi ◽  
Wangxing Lu ◽  
Fan Liu ◽  
Guoqing Zhang ◽  
Feifan Xie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Drug Release ◽  
Combination Therapy ◽  
Tumor Therapy ◽  
Combined Treatment ◽  
Tumor Growth Inhibition ◽  
Target Cells ◽  
Tumor Site

Abstract Background Reactive oxygen species (ROS)-responsive drug delivery systems (DDSs) are potential tools to minimize the side effects and substantially enhance the therapeutic efficacy of chemotherapy. However, it is challenging to achieve spatially and temporally controllable and accurate drug release in tumor sites based on ROS-responsive DDSs. To solve this problem, we designed a nanosystem combined photodynamic therapy (PDT) and ROS-responsive chemotherapy. Methods Indocyanine green (ICG), an ROS trigger and photosensitizer, and pB-DOX, a ROS-responsive prodrug of doxorubicin (DOX), were coencapsulated in polyethylene glycol modified liposomes (Lipo/pB-DOX/ICG) to construct a combination therapy nanosystem. The safety of nanosystem was assessed on normal HEK-293 cells, and the cellular uptake, intracellular ROS production capacity, target cell toxicity, and combined treatment effect were estimated on human breast cancer cells MDA-MB-231. In vivo biodistribution, biosafety assessment, and combination therapy effects were investigated based on MDA-MB-231 subcutaneous tumor model. Results Compared with DOX·HCl, Lipo/pB-DOX/ICG showed higher safety on normal cells. The toxicity of target cells of Lipo/pB-DOX/ICG was much higher than that of DOX·HCl, Lipo/pB-DOX, and Lipo/ICG. After endocytosis by MDA-MB-231 cells, Lipo/pB-DOX/ICG produced a large amount of ROS for PDT by laser irradiation, and pB-DOX was converted to DOX by ROS for chemotherapy. The cell inhibition rate of combination therapy reached up to 93.5 %. After the tail vein injection (DOX equivalent of 3.0 mg/kg, ICG of 3.5 mg/kg) in mice bearing MDA-MB-231 tumors, Lipo/pB-DOX/ICG continuously accumulated at the tumor site and reached the peak at 24 h post injection. Under irradiation at this time point, the tumors in Lipo/pB-DOX/ICG group almost disappeared with 94.9 % tumor growth inhibition, while those in the control groups were only partially inhibited. Negligible cardiotoxicity and no treatment-induced side effects were observed. Conclusions Lipo/pB-DOX/ICG is a novel tool for on-demand drug release at tumor site and also a promising candidate for controllable and accurate combinatorial tumor therapy.

Sign in / Sign up

Export Citation Format

Share Document